Poolbeg Pharma Plc is a clinical-stage infectious disease pharmaceutical company. The firm's capital light clinical model enables to develop multiple products faster than the traditional biotech model. Its portfolio includes POLB 001, Phase II ready, repositioned small molecule immunomodulatory for severe influenza, along with a vaccine discovery platform, PredictViral biomarker platform, and the disease progression data & bio banks that will be interrogated using AI platforms. The company was founded on March 19, 2021 and is headquartered in London, the United Kingdom.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company